These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22357111)

  • 41. Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement.
    Ciccocioppo R; Racca F; Paolucci S; Campanini G; Pozzi L; Betti E; Riboni R; Vanoli A; Baldanti F; Corazza GR
    World J Gastroenterol; 2015 Feb; 21(6):1915-26. PubMed ID: 25684960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Strategic use of immunosuppressants and anti-TNF in inflammatory bowel disease.
    Louis E
    Dig Dis; 2013; 31(2):207-12. PubMed ID: 24030227
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.
    Marzano AV; Borghi A; Meroni PL; Crosti C; Cugno M
    Autoimmunity; 2014 May; 47(3):146-53. PubMed ID: 24437626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Viral Hepatitis in Patients with Inflammatory Bowel Disease].
    Shin SH; Park SH
    Korean J Gastroenterol; 2022 Aug; 80(2):51-59. PubMed ID: 36004631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interferon for the treatment of infections.
    Ho M
    Annu Rev Med; 1987; 38():51-9. PubMed ID: 2437854
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Viral infections in acute graft-versus-host disease: a review of diagnostic and therapeutic approaches.
    Tong LX; Worswick SD
    J Am Acad Dermatol; 2015 Apr; 72(4):696-702. PubMed ID: 25582535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Herpes virus infections: clinical manifestations and therapeutic strategies in immunocompromised patients.
    Saral R; Burns WH; Prentice HG
    Clin Haematol; 1984 Oct; 13(3):645-60. PubMed ID: 6094062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inflammatory bowel disease exacerbation associated with Epstein-Barr virus infection.
    Dimitroulia E; Pitiriga VC; Piperaki ET; Spanakis NE; Tsakris A
    Dis Colon Rectum; 2013 Mar; 56(3):322-7. PubMed ID: 23392146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective monitoring of cytomegalovirus, Epstein-Barr virus, BK virus, and JC virus infections on belatacept therapy after a kidney transplant.
    Bassil N; Rostaing L; Mengelle C; Kallab S; Esposito L; Guitard J; Cardeau-Desangles I; Weclawiak H; Izopet J; Kamar N
    Exp Clin Transplant; 2014 Jun; 12(3):212-9. PubMed ID: 24907721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections.
    Vassilopoulos D; Calabrese LH
    Curr Opin Rheumatol; 2007 Nov; 19(6):619-25. PubMed ID: 17917544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnosis, surveillance, and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of the polymerase chain reaction.
    Schowengerdt KO; Ni J; Denfield SW; Gajarski RJ; Radovancevic B; Frazier HO; Demmler GJ; Kearney D; Bricker JT; Towbin JA
    J Heart Lung Transplant; 1996 Feb; 15(2):111-23. PubMed ID: 8672514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety profile of IBD: lymphoma risks.
    Bewtra M; Lewis JD
    Gastroenterol Clin North Am; 2009 Dec; 38(4):669-89. PubMed ID: 19913208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concomitant infection with three types of virus in a renal transplant recipient.
    Aguado S; Oña M; Martinez A; Gomez E; Fernandez Vega F; Marin R; Alvarez Grande J
    Nephron; 1988; 48(2):161-3. PubMed ID: 2830548
    [No Abstract]   [Full Text] [Related]  

  • 54. [Maternal viral infections as a fetal risk factor].
    Zdziennicki A
    Wiad Lek; 1992 Aug; 45(15-16):619-22. PubMed ID: 1336911
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A practical guide to vaccinating the inflammatory bowel disease patient.
    Wasan SK; Baker SE; Skolnik PR; Farraye FA
    Am J Gastroenterol; 2010 Jun; 105(6):1231-8. PubMed ID: 20104218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Infectious mononucleosis in patients with inflammatory bowel disease under treatment with azathioprine].
    Bargalló A; Carrión S; Domènech E; Arévalo JA; Mañosa M; Cabré E; Cabriada JL; Gassull MA
    Gastroenterol Hepatol; 2008 May; 31(5):289-92. PubMed ID: 18448058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Viral pneumonia in recipients of solid organ transplants.
    Anderson DJ; Jordan MC
    Semin Respir Infect; 1990 Mar; 5(1):38-49. PubMed ID: 2160718
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
    Calvet X; Carpio D; Rodríguez-Lago I; García-Vicuña R; Barreiro-de-Acosta M; Juanola X; Aguas M; Castillo C; Gratacós J
    Gastroenterol Hepatol; 2021 Oct; 44(8):587-598. PubMed ID: 33640469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.
    Bewtra M; Lewis JD
    Expert Rev Clin Immunol; 2010 Jul; 6(4):621-31. PubMed ID: 20594135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response to Tung et al.
    Chaparro M; Gisbert JP
    Am J Gastroenterol; 2013 Apr; 108(4):621-2. PubMed ID: 23552315
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.